Infants with pulmonary arterial hypertension (PAH) who were put on Adempas (riociguat) after Revatio (sildenafil) and other…
Articles by Patricia Inácio, PhD
Children with pulmonary arterial hypertension (PAH) experience lower quality of life because of their functional impairments, especially if they…
Pulmonary hypertension (PH) is linked with changes in the gut microbiome — the vast community of bacteria, fungi, and…
Adempas (riociguat), an approved therapy for adults with pulmonary arterial hypertension (PAH), was well-tolerated in children and adolescents with…
A gene therapy designed to provide a protein implicated in heart function improvement was found to lessen pulmonary blood vessel…
Pulnovo Medical reported that it “successfully concluded” a first meeting with the U.S. Food and Drug Administration (FDA)…
An under-the-skin infusion of a protein called netrin-1 — originally found to regulate nervous system development — shows promise for…
Aerovate Therapeutics‘ AV-101, an inhaled formulation of imatinib for treating pulmonary arterial hypertension (PAH), was well tolerated in…
The levels of blood-circulating inflammatory molecules differ between men and women with pulmonary arterial hypertension (PAH) and correlate with…
A first patient in the U.S. has been dosed in a Phase 2b trial testing Respira Therapeutics‘ inhaled medicine-device…
A bilateral or double lung transplant can rescue heart function in children and adolescents with pulmonary hypertension (PH), a…
Levels of fractional exhaled nitric oxide (FeNO) — a measure of how much nitric oxide a person exhales — may…